Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to see if shorter Photodynamic Therapy (PDT) treatment times will still be effective at treating actinic keratoses (AK) while reducing or eliminating the pain that patients sometimes experience during conventional PDT treatment.
The main questions it aims to answer are:
-
Will the application of the nanoemulsion (10% ALA gel), in the absence of occlusion, still achieve significant inflammation and lesion clearance?
-
Will shortened incubation times of Ameluz still achieve significant inflammation and lesion clearance?
-
Will the new test regimens achieve reduced pain during illumination?
-
Will the new test regimens be safe?
Participants will be randomly assigned to one of three treatment regimens, which will determine the length of time that the topical medication will incubate on the face before red light exposure in PDT treatments. The incubation period will be either 10 minutes, 20 minutes, or 60 minutes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Regimen A Apply topical aminolevulinic acid gel and incubate for 10 minutes prior to red light source |
Drug: Topical aminolevulinate (10% ALA gel)
10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
Other Names:
Device: Red light illumination
Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
Other Names:
|
| Experimental: Regimen B Apply topical aminolevulinic acid gel and incubate for 20 minutes prior to red light source |
Drug: Topical aminolevulinate (10% ALA gel)
10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
Other Names:
Device: Red light illumination
Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
Other Names:
|
| Experimental: Regimen C Apply topical aminolevulinic acid gel and incubate for 60 minutes prior to red light source |
Drug: Topical aminolevulinate (10% ALA gel)
10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
Other Names:
Device: Red light illumination
Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Treatment Efficacy based on Participant AK Lesion Clearance [Lesion clearance at Visit 3 (month 2) and at Visit 4 (month 6)]
To test the hypothesis that a short-contact PDT protocol with Ameluz and red light will produce lesion clearance outcomes that are statistically non-inferior to the traditional, painful protocol. This will be measured by Clinical Efficacy, which will be based on the AK lesion counts and lesion clearance rate after two treatments.
- Differences in Pain Level Reported Throughout Exposure to Red Light [Pain measured during illumination with red light (during a 10 min period) at Visit 1 and at Visit 3]
To demonstrate that a short-contact PDT protocol with Ameluz and red light generates less pain during illumination than the standard FDA-approved protocol currently used. Pain will be reported by the participants during illumination will be measured on a subjective 11-point visual-analog scale (VAS) at 1 min, 5 min, and 10 min.
Secondary Outcome Measures
- Differences in Scores Reported on Patient Satisfaction Survey [At month 6]
To test the hypothesis that a short-contact PDT protocol with Ameluz and red light will be better tolerated and provide higher patient satisfaction than the currently practiced protocol. Participant satisfaction will be measured by completing a Subject Satisfaction Questionnaire survey.
- Number of Participant Reported Adverse Events and side effects [At day 2-4 post-treatment]
Overall AE Profile and Safety of treatment will be measured using an Adverse Events- Patients' side effects log and Investigator assessment.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Minimum of 10 actinic keratoses lesions on the face.
-
Female subjects must not become pregnant during the study
-
Subjects must be able to understand and willing to sign a written informed consent document.
Exclusion Criteria:
-
Pregnant or nursing.
-
Using any topical treatment on their AKs; must stop at least one month prior.
-
Currently undergoing treatment for other cancers with medical or radiation therapy.
-
Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.
-
Patients with history of a photosensitivity disease, such as porphyria cutanea tarda.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cleveland Clinic, Dermatology and Plastic Surgery Institute, Case Comprehensive Cancer Center | Cleveland | Ohio | United States | 44195 |
Sponsors and Collaborators
- Case Comprehensive Cancer Center
- The Cleveland Clinic
- Biofrontera, Inc.
Investigators
- Principal Investigator: Edward V Maytin, M.D. Ph.D., Cleveland Clinic, Dermatology and Plastic Surgery Institute, Case Comprehensive Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CASE4623